Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis

Breast

Volumn 22, Issue 1, 2013, Pages 19-23

  Torrejón, Davis ^a   Oliveira, Mafalda ^a   Cortes, Javier ^a   Sanchez Olle, Gessami ^a   Gómez, Patricia ^a   Bellet, Meritxell ^a   Saura, Cristina ^a   Peg, Vicente ^a   Rovira, Alex ^a   Di Cosimo, Serena ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer subtypes; Leptomeningeal carcinomatosis; Systemic chemotherapy

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN RADIATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CLINICAL FEATURE; HUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC THERAPY;

EID: 84871714970     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.10.009     Document Type: Article

References (35)

1. Kesari S., Batchelor T.T. Leptomeningeal metastases. Neurol Clin 2003, 21:25-66.
2. Lee Y.T. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983, 23:175-180.
3. Tsukada Y., Fouad A., Pickren J.W., Lane W.W. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983, 52:2349-2354.
4. Rudnicka H., Niwinska A., Murawska M. Breast cancer leptomeningeal metastasis-the role of multimodality treatment. J Neurooncol 2007 Aug, 84(1):57-62.
5. Chamberlain M.C., Kormanik P.R. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997, 35:55-64.
6. Chamberlain M.C. Leptomeningeal metastasis. Curr Opin Oncol 2010 Nov, 22(6):627-635.
7. Gauthier H., Guilhaume M.N., Bidard F.C., Pierga J.Y., Girre V., Cottu P.H., et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol 2010 Apr 29.
8. Kennecke H., Yerushalmi R., Woods R., Chon Cheang M., Voduc D., Speers C., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010 Jul 10, 28(20):3271-3277.
9. Bidard F.C., Guilhaume M.N., Gauthier H., Cottu P.H., Dieras V., Pierga J.Y. Meningeal carcinomatosis in HER2-overexpressing breast cancers. J Neurooncol 2009 Jun, 93(2):287-288.
10. Boogerd W., Hart A.A., van der Sande J.J., Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991 Mar 15, 67(6):1685-1695.
11. de Azevedo C.R., Cruz M.R., Chinen L.T., Peres S.V., Peterlevitz M.A., de Azevedo Pereira A.E., et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neurooncol 2011 Jan 14.
12. Jayson G.C., Howell A., Harris M., Morgenstern G., Chang J., Ryder W.D. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 1994 Dec 15, 74(12):3135-3141.
13. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
14. Niwinska A.M., Rudnicka H., Murawaska M. Breast cancer carcinomatous meningitis: differences in survival depending on biological subtype, performance status, and treatment methods. J Clin Oncol 2011, 29. [suppl.; abstr 1073].
15. Kotecki N., Le Rhun E., Baranzelli M., Faivre-Pierret M., Zairi F., Duboi F., et al. Pathological characteristics and prognosis of a cohort of 74 patients (pts) with breast cancer (BC) with neoplastic meningitis (NM). J Clin Oncol 2010, 28(7s).
16. Straathof C.S., de Bruin H.G., Dippel D.W., Vecht C.J. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999, 246(9):810.
17. Freilich R.J., Krol G., DeAngelis L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995, 38(1):51.
18. Chamberlain M.C. Comparative spine imaging in leptomeningeal metastases. J Neurooncol 1995, 23(3):233.
19. Lin N.U., Bellon J.R., Winer E.P. CNS smetastases in breast cancer. J Clin Oncol 2004 Sep 1, 22(17):3608-3617.
20. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010 Apr 1, 28(10):1684-1691.
21. Burstein H.J., Liebeman G., Slamon D.J., Winer E.P., Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005, 16:1772-1777.
22. Kallioniemi O.P., Holli K., Visakorpi T., Koivula T., Helin H.H., Isola J.J. Association od c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991, 49:650-655.
23. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid altered in HER2- positive breast cancer patients with brain metastases and impairment of blood- brain barrier. Anticancer Drugs 2007, 18:23-28.
24. Ferrario C., Davidson A., Bouganim N., Aloyz R., Panasci L.C. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009, 20:792-795.
25. Oliveiram Braga S., Passos-Coelho J.L., Fonseca R., Oliveira J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 2011, 127:841-844.
26. Stemmler H.J., Schmitt M., Harbeck N., Willems A., Bernhard H., Lassig D., et al. Application of intrathecal trastuzumab (herceptintrade mark) for treatment of meningeal carcinomatosis in HER2- overexpressing metastatic breast cancer. Oncol Rep 2006, 15:1373-1377.
27. Jaeckle K.A., Phuphanich S., Bent M.J., Aiken R., Batchelor T., Campbell T., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001 Jan, 84(2):157-163.
28. Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 2010 Sep, 11(9):871-879.
29. Glas M., Stuplich M., Tschampa H., Urbach H., Rasch K., Herrlinger U. Liposomal cytarabine given concomitantly with radiotherapy in a patient with leptomeningeal metastasis from breast cancer. J Neurol 2008, 255(11):1838-1839.
30. Hoffmann A.L., Buhk J.H., Strik H.A. Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal ara-c combined with dose-dense temozolmide. Anticancer Res Dec 2009, 29(12):5191-5195.
31. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009 Nov 1, 27(31):5278-5286.
32. Nam B.H., Kim S.Y., Han H.S., Kwon Y., Lee K.S., Kim T.H., et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008, 10(1):R20.
33. Church D.N., Modgil R., Guglani S., Bahl A., Hopkins K., Braybrooke J.P., et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008 Jun, 31(3):250-254.
34. Bartsch R., Rottenfusser A., Wenzel C., Dieckmann K., Pluschnig U., Altorjai G., et al. Trastuzumab prolongs overall survival in patients with brain metastases from HER2 positive breast cancer. J Neurooncol 2007 Dec, 85(3):311-317.
35. Bidard F.C., Lossignol D., Larsimont D., Piccart M., Awada A. Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis. Ann Oncol 2011 Feb, 22(2):480-482.